Press & events

What's happening?

Stay updated on our latest news and events.

Displaying 71 - 80 of 92

Insights

Oncopeptides have collaborated with Recipharm to help bring their anti-cancer treatment to life.

Oncopeptides is a clinical stage company that is developing a molecule for oncologyindications. The molecule, which originated at Uppsala University, Sweden and the Karolinska Institute, is focused on multiple myeloma as a first indication.

Insights

Serialisation represents a significant challenge for CDMOs, with multiple factors to consider, from varying market regulations to data storage and exchange.  

Insights

With US serialisation requirements about to come into force and EU regulations on the horizon, more and more businesses are considering what track and trace could mean for them beyond compliance.

Insights

ABSTRACT: Aminopeptidases like aminopeptidase N (APN, also known as CD13) play an important role not only in normal cellular functioning but also in the development of cancer, including processes like tumor cell invasion, differentiation, proliferation, apoptosis, motility, and angiogenesis.

Insights

Demand for outsourced contract manufacturing in the pharmaceutical industry continues to grow, but what does it take to be a trusted partner?

Insights

The current pharmaceutical industry landscape creates some interesting opportunities for CDMOs to grow and develop.

Insights

In the last ten years, the contract manufacturing sector has experienced some major changes as a result of consolidation, increasing price pressures and evolving customer expectations.

Insights

Amjad Alhalaweh, one of our formulation scientists at Recipharm, took part in the in-Pharma Technologist Drug Delivery online conference on Thursday 20th April, 2017.

Insights

As the need to manufacture more challenging drugs for smaller patient populations increases so too does the demand for aseptic manufacturing.

Highly potent oncology drugs and injectables are driving the demand for CDMOs to meet the stringent regulatory requirements surrounding the manufacture of sterile products.  

Insights

During the discovery and early stages of drug development the pharmacology, pharmacokinetics and toxicology of a compound are evaluated using a simple liquid formulation. However, low aqueous solubility can prove to be a major obstacle when it comes to the development of liquid formulations, so selecting the right excipients to help solubilise them is vital.